PMID- 24474384
OWN - NLM
STAT- MEDLINE
DCOM- 20141107
LR  - 20211021
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Print)
IS  - 0017-5749 (Linking)
VI  - 63
IP  - 10
DP  - 2014 Oct
TI  - Use of proton pump inhibitors after antireflux surgery: a nationwide 
      register-based follow-up study.
PG  - 1544-9
LID - 10.1136/gutjnl-2013-306532 [doi]
AB  - OBJECTIVE: Antireflux surgery (ARS) has been suggested as an alternative to 
      lifelong use of proton pump inhibitors (PPI) in reflux disease. Data from 
      clinical trials on PPI use after ARS have been conflicting. We investigated PPI 
      use after ARS in the general Danish population using nationwide healthcare 
      registries. DESIGN: A nationwide retrospective follow-up study of all patients 
      aged >/=18 and undergoing first-time ARS in Denmark during 1996-2010. Two outcome 
      measures were used: redemption of first PPI prescription after ARS (index 
      prescription) and a marker of long-term use, defined by an average PPI use of 
      >/=180 defined daily doses (DDDs) per year. Kaplan-Meier curves and Cox 
      proportional hazards model were used for statistics. RESULTS: 3465 patients 
      entered the analysis. 12.7% used no PPI in the year before surgery, while 14.2%, 
      13.4% and 59.7% used 1-89 DDD, 90-179 DDD and >/=180 DDD, respectively. Five-, 10- 
      and 15-year risks of redeeming index PPI prescription were 57.5%, 72.4% and 
      82.6%, respectively. Similarly, 5-, 10- and 15-year risks of taking up long-term 
      PPI use were 29.4%, 41.1% and 56.6%. Female gender, high age, ARS performed in 
      most recent years, previous use of PPI and use of nonsteroidal anti-inflammatory 
      drugs or antiplatelet therapy significantly increased the risk of PPI use. 
      CONCLUSIONS: Risk of PPI use after ARS was higher than previously reported, and 
      more than 50% of patients became long-term PPI users 10-15 years postsurgery. 
      Patients should be made aware that long-term PPI therapy is often necessary after 
      ARS.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Lodrup, Anders
AU  - Lodrup A
AD  - Department of Medicine, Koge University Hospital, University of Copenhagen, Koge, 
      Denmark.
FAU - Pottegard, Anton
AU  - Pottegard A
AD  - Clinical Pharmacology, Institute of Public Health, University of Southern 
      Denmark, Odense, Denmark Department of Clinical Chemistry & Pharmacology, Odense 
      University Hospital, Odense, Denmark.
FAU - Hallas, Jesper
AU  - Hallas J
AD  - Clinical Pharmacology, Institute of Public Health, University of Southern 
      Denmark, Odense, Denmark Department of Clinical Chemistry & Pharmacology, Odense 
      University Hospital, Odense, Denmark.
FAU - Bytzer, Peter
AU  - Bytzer P
AD  - Department of Medicine, Koge University Hospital, University of Copenhagen, Koge, 
      Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140128
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Denmark
MH  - Female
MH  - Follow-Up Studies
MH  - Gastroesophageal Reflux/*drug therapy/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Registries
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4173662
OTO - NOTNLM
OT  - Anti-Reflux Surgery
OT  - Gastroesophageal Reflux Disease
OT  - Proton Pump Inhibition
EDAT- 2014/01/30 06:00
MHDA- 2014/11/08 06:00
CRDT- 2014/01/30 06:00
PHST- 2014/01/30 06:00 [entrez]
PHST- 2014/01/30 06:00 [pubmed]
PHST- 2014/11/08 06:00 [medline]
AID - gutjnl-2013-306532 [pii]
AID - 10.1136/gutjnl-2013-306532 [doi]
PST - ppublish
SO  - Gut. 2014 Oct;63(10):1544-9. doi: 10.1136/gutjnl-2013-306532. Epub 2014 Jan 28.